Interleukin-34 sustains inflammatory pathways in the gut
In conclusion, data indicate that IL-34 is up-regulated in IBD and suggest a role for this cytokine in sustaining the inflammatory responses in this disease.
Conclusions: Anorectal function is impaired in IBD patients with perianal disease. Fecal incontinence correlates with poorer quality of life. Anorectal manometry and ultrasonography are useful tools for evaluating IBD patients. PMID: 31625422 [PubMed - as supplied by publisher]
Tim G.J. de Meij Endoscopic evaluation is mandatory in establishing the diagnosis of pediatric inflammatory bowel disease (IBD), but unfortunately carries a high burden on patients. Volatile organic compounds (VOC) have been proposed as alternative, noninvasive diagnostic biomarkers for IBD. The current study aimed to assess and compare the potential of fecal and urinary VOC as diagnostic biomarkers for pediatric IBD in an intention-to-diagnose cohort. In this cohort study, patients aged 4–17 years, referred to the outpatient clinic of a tertiary referral center under suspicion of IBD, were eligible to par...
Authors: Mahamid M, Bar-Gil Shitrit A, Amara H, Koslowsky B, Ghantous R, Safadi R Abstract BACKGROUND: Crohn's disease and ulcerative colitis are the two major classic presentations of inflammatory bowel diseases (IBD). Studies have shown a wide variation in the incidence and prevalence attributed to different geographic and ethnic populations. OBJECTIVES: To assess the clinical characteristics of IBD among Arabs in Israel and to compare them to characteristics of IBD among Ashkenazi Jews. METHODS: This retrospective, comparative study compared the clinical characteristics of IBD among 150 Arabs from the Ho...
Elective abdominal surgery for inflammatory bowel disease is common. Surgery for Crohn ’s disease is not curative, and treatment must be individualized to the disease process. Surgery for ulcerative colitis generally is curative but consideration of patient-specific factors is important for staging of the procedure and determining whether ileal pouch–anal anastomosis is appropriat e.
CONCLUSION: In this study, we demonstrate that risk factors for NAFLD and LF in the IBD population do not differ from those in the general population. PMID: 31602167 [PubMed - in process]
ConclusionCombination therapy with 50 mg allopurinol led to a decrease of 6-TGN levels compared with 100 mg allopurinol. Disease activity, side effects, and patient experience, however, were similar between allopurinol 100 and 50 mg. UC patients seem to benefit and prefer lower doses whereas the contrary is seen in CD patients.Trial registrationEudraCT trial registry - number2016-001638-84
Conclusions: We demonstrate that the risk of relapse in ulcerative colitis can be predicted by consecutively measuring faecal EDN every third month, and suggest EDN as a complementary faecal marker to calprotectin to predict future relapse in ulcerative colitis. Our finding of higher EDN in Crohn's disease-patients staying in remission than in those who relapsed indicates different functions of the protein in ulcerative colitis and Crohn's disease. PMID: 31577465 [PubMed - as supplied by publisher]
Conclusions: Defining the landscape of MNPs in MLNs provided evidence for expansion of CD163+ Mono/MΦ-like cells in UC only, highlighting a distinction between UC and CD, and thus the potential co ntribution of monocyte-like cells in driving colitis.
Although the number of available therapies for the treatment of ulcerative colitis (UC) and Crohn ’s disease (CD) continues to expand, a significant portion of patients with inflammatory bowel disease (IBD) will require surgical intervention. Surgery remains an integral part of the treatment algorithm for patients with UC and CD, and thus multidisciplinary approaches to the perioperative and p ostoperative management of patients with IBD are critical to improving outcomes during these periods. New mechanisms of biologic therapies are emerging and new treatment strategies focused on earlier and potentially more aggres...
Condition: Ulcerative Colitis Intervention: Drug: Tauroursoursodeoxycholic acid, brand name Tudcabil Sponsors: Washington University School of Medicine; Crohn's and Colitis Foundation Recruiting